Sugi Predict

Sugi Predict / Compounds / SCHEMBL1738428

SCHEMBL1738428

SCHEMBL1738428

Nc1nc2c(ncn2[C@@H]2O[C@H](CO)C(CF)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.60
▸ HINT1 P49773 4/20 0.58
▸ NT5E P21589 2/20 0.58
▸ STING1 Q86WV6 2/20 0.55
▸ PDE3B Q13370 1/20 0.55
▸ PDE3A Q14432 1/20 0.55
▸ GSK3A P49840 2/20 0.54
▸ RPS6KA3 P51812 2/20 0.54
▸ MAPK14 Q16539 2/20 0.54
▸ PNP P00491 2/20 0.54
▸ TGM2 P21980 1/20 0.54
▸ LMNA P02545 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ PAX8 Q06710 1/20 0.52
▸ ADORA2A P29274 1/20 0.51
▸ ADORA2B P29275 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12150668 1.00 HPGD (0.60) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL12746827 1.00 HPGD (0.60) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL1738430 1.00 HPGD (0.60) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL12031078 1.00 HPGD (0.60) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL1738429 1.00 HPGD (0.60) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL25711664 0.93 HPGD (0.64) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL20248685 0.93 HPGD (0.64) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL17198349 0.93 HPGD (0.64) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL17198483 0.91 HPGD (0.61) HPGDHINT1NT5ESTING1PDE3B
SCHEMBL1875985 0.89 HPGD (0.71) HPGDHINT1NT5ESTING1PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2360166-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase Merck Sharp & Dohme Corp. (US) 2011-08-24 — — EP claimed
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase MERCK SHARP & DOHME LLC 2004-06-10 — — US claimed
US-20170183373-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE MERCK SHARP & DOHME CORP. (US) 2017-06-29 — — US disclosed
US-20140309412-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE IONIS PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-8481712-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME CORP. (US) 2013-07-09 — — US disclosed
US-20120165515-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2012-06-28 — — US disclosed
EP-2399588-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase Merck Sharp & Dohme Corp. (US) 2011-12-28 — — EP disclosed
EP-2360166-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase Merck Sharp & Dohme Corp. (US) 2011-08-24 — — EP disclosed
US-20070275912-A1 Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase MERCK SHARP & DOHME CORP. 2007-11-29 — — US disclosed
US-7202224-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK & CO., INC. (US) 2007-04-10 — — US disclosed
US-20060264390-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase IONIS PHARMACEUTICALS, INC. 2006-11-23 — — US disclosed
US-7105499-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK & CO., INC. (US) 2006-09-12 — — US disclosed
US-20050272676-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase BHAT BALKRISHEN 2005-12-08 — — US disclosed
US-6777395-B2 VIRICIDES MERCK & CO., INC. 2004-08-17 — — US disclosed
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase MERCK SHARP & DOHME LLC 2004-06-10 — — US disclosed
US-20040072788-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase BHAT BALKRISHEN (US) 2004-04-15 — — US disclosed
US-20040067901-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2004-04-08 — — US disclosed
US-20040014957-A1 Oligonucleotides having modified nucleoside units ISIS PHARMACEUTICALS, INC. 2004-01-22 — — US disclosed
WO-2003099840-A1 OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS ISIS PHARMACEUTICALS, INC. (US) 2003-12-04 — — WO disclosed
US-20020147160-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2002-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067901-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885
US-20040014957-A1 Oligonucleotides having modified nucleoside units RNASE1, RNASEH1, RNASEL HPGD 4648/4885HINT1 345/4885NT5E 161/4885
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase NSUN2, NSUN3, POLRMT HPGD 2317/4885HINT1 567/4885NT5E 46/4885
US-20170183373-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE POLRMT, DUT, RNASE1 HPGD 2394/4885HINT1 620/4885NT5E 33/4885
US-20060264390-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885
US-20040072788-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885
US-20140309412-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885
US-20050272676-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885
US-20020147160-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885
US-20120165515-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885
US-20070275912-A1 Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT HPGD 2235/4885HINT1 778/4885NT5E 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.